National and Kapodistrian University of Athens
Αξιολόγηση της PET/CT scan σε συνδυασμό με MRI εγκεφάλου, ως μοναδικού τρόπου σταδιοποίησης του μn - μικροκυτταρικού καρκίνου του πνεύμονα: προοπτική καταγραφή της ακρίβειας, της αξιοπιστίας και του κόστους
Abstract
dc:descriptionLung cancer is one of the most aggressive forms of cancer and worldwide it is the leading cause of death among men and women. The main cause for lung cancer is smoking, while pollution and other chemicals play a smaller role. 80-85% of cases of lung cancer are non-small cell lung cancer (NSCLC). Accurate information on the initial tumor spreading (tumor staging) is critical in order to plan the optimal therapeutic strategy and improve prognosis. Surgery is still the best attempt to treat the early stage tumors of NSCLC, but as it is a severe surgery with various complications, it is not the ideal therapeutic strategy for every patient with NSCLC. Futile thoracotomies should be avoided because patient's life expectancy may be reduced and quality of life be worsened.The primary objective of this thesis is to evaluate if PET/CT scan in combination with brain MRI as the only way to stage non-small cell lung cancer is accurate, reliable and cost-effective.For the purpose of this study, from December 2014 we collected and prospectively recorded the data of 30 newly diagnosed NSCLC patients in Greece, who were referred for oncological assessment and treatment to the Oncology Unit of the 3rd Department of Medicine of National and Kapodistrian University of Athens Medical School, hosted in the General Hospital of Thoracic Diseases of Athens "Sotiria", until November 2016. Data were derived from the Oncology Unit’s medical records. Recording and follow-up of incidents was done using the archived clinical information in the patients’ files. The diagnostic and treatment process was followed until the day recording was completed. Dates, diagnoses and investigation costs for each patient were collected throughout the data period recording (CT, PET/CT, brain MRI, cytological and histological tests, repeated investigations, chemotherapy cycles, surgery, days of hospitalization).These patients were also staged with thoracic CT scan and with a combination of PET/CT and brain MRI, but the decision whether or not to undergo surgery was based on PET/CT staging. Positive brain MRI was used to exclude patients and only patients staged from IA to IIIA by the CT imaging were included. Moreover, patients were excluded if their visit to the oncologist was after a successful or futile surgery.This study showed a divergence among staging with CT alone or PET/CT alone occurred in 50% of the cases. The use of PET/CT also revealed metastases that were undetectable by the CT (20% of the cases) or nodal metastases that were underestimated (26.7% of the cases), as well as differentiation in T staging (30% of the cases). The patients were divided into 3 groups, those who were operated after PET/CT staging (7), those who had to undergo chemotherapy before surgery (9) and those who remained inoperable even after the neo-adjuvant chemotherapy treatment (14).Based on CT staging, 9 patients could go directly to surgery without further imaging procedure and/or chemotherapy, of which only 3 could really go directly to a curative resective surgery. Of the remaining 6 patients, 3 had firstly to undergo chemotherapy and the other 3 were significantly understaged compared to the PET/CT staging and proved to be inoperable. Thus, 10% of unnecessary thoracotomies were completely avoided while another 10% of cases underwent surgery after neoadjuvant chemotherapy and had a better prognostic imaging.In patients with neoadjuvant chemotherapy who then underwent a thoracotomy, a significant improvement in patient physical condition and a desirable understaging was observed, comparing the pathologic staging with the clinical (based on PET/CT) in 8 out of 9 patients.Average cost for direct thoracotomy was 6,066€, for those who needed chemotherapy previously was 9,068€ and for inoperable patients with palliative therapy 5,109€, while the average cost for both PET/CT and brain MRI was about 1,330€ (for the primary tests) and the average cost of a surgical intervention was 4,500€. It seems reasonable to use PET/CT staging to choose the optimal treatment strategy and proceed or not in a resection in NSCLC patients. Not only from the financial point of view, but also by taking into consideration the possible complications during and soon after surgery, as well as the fact that recovering from lung cancer surgery typically takes weeks to months.In conclusion, accurate staging of patients with NSCLC plays a significant role in determining the adequate treatment strategy and optimizing the patient prognosis. The combination of PET/CT and brain MRI can provide a reliable method for tumor and nodal staging plus distant metastasis detecting, reducing unnecessary thoracotomies and its associated morbidity and costs.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Gkogkozotou, Vasiliki-Konstantina
- Γκογκοζώτου, Βασιλική-Κωνσταντίνα
Subjects
dc:subject × 17- Ακρίβεια
- Αποτελεσματικότητα
- Θωρακοτομή
- Μη - μικροκυτταρικός καρκίνος πνεύμονα (ΜΜΚΠ)
- Οικονομικά της Υγείας
- Σταδιοποίηση
- Accuracy
- Health economics
- Non - small cell lung cancer (NSCLC)
- PET/CT
- Reliability
- Staging
- Thoracotomy
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
dc:rights- Statement dc:rights
-
- BY_NC_ND
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44348